Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Insite Vision

Sort by

InSite Vision: Positive Phase III Trial Results for BromSite Reduces Much of Downside Risk in the Stock (INSV.OB, $0.30)

Tuesday, March 19, 2013 · 9:29 am

Read More

InSite Vision: Upcoming Topline Results from Clinical Trials Presents a Buying Opportunity (INSV.OB, $0.34)

Monday, December 17, 2012 · 11:02 am

Read More

Hitting Major Milestones is Driving InSite's Price (INSV.OB, $0.40)

Wednesday, September 12, 2012 · 8:15 am

Read More

InSite Vision: Initiation of Coverage on Promising Late Stage Ophthalmology Company (INSV, $0.30)

Wednesday, June 20, 2012 · 2:46 pm

Read More

There are 4 reports on file.

« Back to Company Reports Index